3 FTSE Shares You Should Have Bought Last Week: Mulberry Group PLC, Hargreaves Lansdown plc and Hikma Pharmaceuticals Plc

The FTSE 100 (INDEXFTSE:UKX) got trounced this week by Mulberry Group PLC (LON: MUL), Hargreaves Lansdown plc (LON: HL) and Hikma Pharmaceuticals Plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Last week the FTSE 100 (FTSEINDICES: ^FTSE) closed down 185 points, or 2.75%, on the start of the week. Investors were spooked ahead of the referendum in Crimea and economic data indicated a slowdown in China.

If you kept your nerve and bought shares — a great business is still a great business, no matter what market sentiment is — then you might have picked up a bargain or two.

Here are some of the top risers:

Mulberry 

MulberryShares in Mulberry (LSE:  MUL) hiked 5% this week after the chief executive, Bruno Guillon, resigned after serving two years in the role. His tenure had not been successful.

Earlier this year Mulberry’s shares plunged 24% after announcing another profit warning. Guillon stated at the time that the company “continues to invest in the ongoing process of transforming Mulberry from a domestic to a global luxury brand.”

That was his failing. The result of this strategy was a steep hike in prices, that put off consumers. Mulberry has been rudderless for some time after the brand’s creative director, Emma Hill, resigned last summer in opposition to the new direction.

Mulberry’s previous success was based on designs that were expensive, but not out of reach, for many British shoppers. Even in 2009, during the recession, UK sales improved 40%.

Today? Nobody’s buying a Mulberry bag that costs upwards of £1,000. Instead, customers have defected to cheaper brands such as Coach and Michael Kors.

Godfrey Davis, the company’s chairman, will take over until a successor is found.

Hargreaves Lansdown

_ISA2Hargreaves Lansdown (LSE: HL) was a big beneficiary from George Osborne’s Budget announcement on Wednesday. The shares are up 11% since the beginning of the week.

The gains came at the expense of leading insurers, such as Aviva and Legal & General — which fell 11% and 7% respectively — after it was announced that pensioners will no longer require an annuity to remove money from their pension pot.

Hargreaves Lansdown, the UK’s largest investment platform, should receive an upswing in business as pensioners take their savings as a lump sum and invest money in the stock market.

A similarly favourable news snippet was the announcement that ISAs, which currently exist in two forms — cash and stocks — will be merged into a single “New ISA” with a higher annual savings limit of £15,000. Hargreaves sells ISAs, and again, will benefit here.

Hikma Pharmaceuticals

astrazenecaAnalysts were widely predicting Hikma Pharmaceuticals’ (LSE: HIK) final results would show a 90% earnings increase. The shares have been thriving on these expectations.

When the official figures were unveiled they smashed the forecasts, coming in at 111%, and the share price has increased 7% on last week.

Since the beginning of the year Hikma’s gains have more than tripled the leading blue-chip pharma companies GlaxoSmithKline and AstraZeneca combined. Being a smaller company, Hikma Pharmaceuticals is potentially a more attractive growth stock than its larger brethren.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Mark does not own shares in any company mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Senior couple crossing the road on a city street. They are walking with shopping bags while Christmas shopping.
Investing Articles

9.4% yield! A magnificent dividend stock I’d buy to target a lifelong second income

Royston Wild’s creating a list of the London stock market's best dividend shares. Here's one he's hoping to buy for…

Read more »

Investing Articles

£17,000 in savings? Here’s how I’d target a weighty passive income

Funnelling any spare savings towards building a passive income is certainly a smart idea, but how to find the right…

Read more »

Investing Articles

Why is this FTSE 250 giant up 35% in two weeks?

Seeing a share price soaring can often be a reason to be cautious, but I still think there's a lot…

Read more »

Light bulb with growing tree.
Investing Articles

Is there still time to snap up this ex-penny stock in May?

A penny stock no more but a promising low-cap company nonetheless. Our writer examines the growth prospects of this sustainable…

Read more »

Close-up of British bank notes
Investing Articles

Here’s how I’d target a £1,890 second income by investing £35 a week

Christopher Ruane explains how, for a fiver a day, he'd aim to build a second income of almost £1,900 in…

Read more »

Dividend Shares

£5k in savings? Here’s how I’d try to turn it into £414 of monthly passive income

Jon Smith explains how he'd use both dividend and growth shares to help him take a lump sum of £5k…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Warren Buffett’s sitting on $189bn in cash. What’s this telling us?

Legendary stock market investor Warren Buffett's currently sitting on a cash pile bigger than most FTSE 100 companies. Is this…

Read more »

Typical street lined with terraced houses and parked cars
Dividend Shares

Here’s how much income I’d make if I invested all my ISA in Taylor Wimpey shares

Jon Smith explains why researching Taylor Wimpey shares could be a good move, based on historical dividend payments and the…

Read more »